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Abstract End-stage liver disease caused by chronic hepatitis C virus
(HCV) infection is a leading cause for liver transplantation (LT). Due
to viral evasion from host immune responses and the absence of pre-
ventive anti-viral strategies, reinfection of the graft is universal. The
mechanisms by which the virus evades host immunity to re-infect
the liver graft are unknown. In a longitudinal analysis of six HCV-
infected patients undergoing LT, we demonstrate that HCV variants
re-infecting the liver graft were characterized by efﬁcient entry
and poor neutralization by antibodies present in pre-transplant
serum compared with variants not detected after transplantation.
Monoclonal antibodies directed against HCV envelope glycoproteins
or a cellular entry factor efﬁciently cross-neutralized infection of
human hepatocytes by patient-derived viral isolates that were resis-
tant to autologous host-neutralizing responses. These ﬁndings pro-
vide signiﬁcant insights into the molecular mechanisms of viral
evasion during HCV reinfection and suggest that viral entry is a via-
ble target for prevention of HCV reinfection of the liver graft.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
End-stage liver disease or hepatocellular carcinoma related to
chronic hepatitis C infection is a frequent indication of the need
for liver transplantation (LT) worldwide. HCV infection systemat-
ically recurs after liver transplantation [1] leading to cirrhosis,
graft loss, and lower survival. Hepatitis C is a chronic infectionJournal of Hepatology 20
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E-mail address: feray.cyrille@neuf.frthat displays antibody-mediated neutralization [2]. Numerous
papers have reported the possibility of neutralizing HCV infection
in cell culture and in animal models. HCV is a quasispecies com-
posed of quasi homologous variants that continuously escape cel-
lular or humoral immunity as well as anti-viral therapies, and
this probably plays a central role in the development of chronic
infection. After liver transplantation, the quasispecies change
and only one part of the pre-transplant variants re-infects the
liver graft: this is the bottleneck effect.
In a longitudinal and very precise analysis of six patients
infected by genotype 1b who underwent liver transplantation,
Thomas Baumert et al. [3] showed that all studied HCV vari-
ants re-infecting the liver graft were characterized by efﬁcient
entry and poor neutralization by antibodies present in pre-
transplant serum. Conversely, pre-transplant subvariants not
detected soon after liver transplantation were characterized
by less effective hepatocyte entry. Most importantly, they
demonstrated that all non-selected HCV subvariants were
effectively neutralized by autologous patient serum in all stud-
ied cases. The major interest of the liver transplantation model
is to show that successful neutralization does not depend
solely on the afﬁnity between neutralizing antibodies and
HCV, which is expected, but also on the afﬁnity between
HCV and cellular receptor(s).
This study is another illustration demonstrating the utility of
HCV pseudoparticles (HCVpps) and their role in HCV cell entry.
HCVpp have been shown to represent a robust and valid system
for the study of HCV entry and antibody-mediated neutralization
[2]. In the present work, the clinical sequences corresponding to
selected and non-selected subvariants were used for the synthe-
sis of HCVpp. In this elegant model, mutations in the viral region
involved in the binding of HCV to cell receptors such as the tetra-
spanin CD81 can be tested.
For the ﬁrst time, this study also shows that cross-reactive
monoclonal antibodies such as mAb AP33 can neutralize the
infection of viral variants that are resistant to host-neutralizing
responses. The original approach is also to block cell receptors,
as in the present paper, the tetraspanin, CD81. In a previous paper
from the same team, the blocking of Claudin 1, another HCV
receptor, was also effective in preventing hepatocytes from
HCVpp infections [3]. This clearly opens the way for the develop-
ment of novel preventive strategies and improved management
of the HCV-infected patient undergoing LT.
The main problem with blocking HCV entry, either at the viral
or the cellular level, is quantitative. The most relevant model for11 vol. 54 j 825–826
Fig. 1. Prevention of post LT HCV recurrence may combine anti-viral therapies before or after LT and passive or active immunotherapies during and after LT.
International Hepatologyliver transplantation is preventing the recurrence of HBV. Anti-
HBs (HBIG) are highly potent neutralizing antibodies. However,
neutralization with HBIG usually fails in case of high HBV loads
before transplantation (>100,000 copies/ml). This is also true for
the prevention of post-natal transmission of HBV in mothers with
high levels of replication during pregnancy. A previous trial using
polyclonal anti-HCV failed to prevent recurrence after liver trans-
plantation in viremic patients [4]. Blocking cell receptors such as
CD81 in this paper raises the same quantitative issue. CD81 is a
member of the transmembrane pore integral membrane protein
family; it has a broad tissue distribution since the liver is a large
organ and complete blockage of this receptor is therefore a chal-
lenge. Furthermore, its function had not been previously identi-
ﬁed. In cell culture, antibodies against CD81 induce aggregation
of cells and can inhibit their growth. Effective blockage may
therefore result in unexpected adverse events.
How can we explain the main ﬁnding that shows a reduced
neutralization and the more efﬁcient cell entry of variants
selected after transplantation? The role of lipoproteins is not
mentioned probably because, although HCVpp are derived from
clinical strains, they are artiﬁcial constructs. One could hypothe-
size that escape variants may be both poorly neutralized and
more efﬁcient for cell entry because the envelope is more or less
effectively linked to lipoproteins. The HCVpp used in experiments
are produced by human cell lines which probably contain lipo-
proteins that could inhibit hepatitis C virus-neutralizing antibod-
ies or stimulate cell entry.
Finally, we would like to summarize the other current
approaches used to avoid HCV recurrence (Fig. 1). The ﬁrst, which
has been available for years, is to cure HCVwith traditional bither-
apy before LT [5]. In this case, no recurrence occurs but it is difﬁcult
to achieve in patientswith cirrhosis on thewaiting list. Speciﬁcally
targeted anti-viral therapies (STAT-C) will certainly change results
in this ﬁeld in the near future. Another approach is antibody-med-
iated neutralization which has been unsuccessfully attempted in
patients with uncontrolled viremia [4]. Once again, STAT-C should826 Journal of Hepatology 201change the efﬁcacy of neutralization with polyclonal or monoclo-
nal antibodies. Adoptive immunotherapy has also been attempted,
using lymphocytes extracted from the liver allograft perfusate,
which includes an abundance of allogenous NK/NKT cells that
mount an anti-HCV response in HCV-infected liver transplantation
recipients, despite the immunosuppressive environment [6]. As
for HBV, the goal of less than 10% viral recurrence after liver trans-
plantation can be achieved; the combination of potent direct-act-
ing anti-viral therapy as well as an additional post-transplant
approach seems to be a valuable option in these cases.
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